Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The shape of the predicted sales launch curve can dramatically affect financial models of pre-commercial drugs. This article provides an update on a commonly used framework for modelling launch curves.
This article analyses recent data on the reported causes of drug candidate attrition, which indicate that lack of efficacy is the reason for approximately half of all phase II and phase III failures.
Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease, is predicted to become the leading reason for liver transplantation by 2020. This analysis provides an overview of emerging therapies for NASH.
Recent investments in nascent public biopharmaceutical companies indicate that companies focused on small-molecule approaches attracted more funding than might have been expected based on rates of return on investment compared with biologic approaches.
Traditional cytotoxic chemotherapies have been the mainstay of treatment for bladder cancer for decades, but targeted biologics are now becoming available. This article analyses the late-stage pipeline for bladder cancer and the impact of new drugs in this rapidly growing market.
The standard of care for the treatment of acute myeloid leukaemia (AML) has changed little for decades, but there are now a number of interesting agents in development. This analysis overviews the late-stage AML pipeline and the changing AML market.
Key emerging therapies for HIV include novel combination regimens as well as extended-duration antiretroviral drugs. This article provides an overview of novel drugs and combinations in the pipeline, as well as an analysis of the current HIV drug market.
This analysis of the industry's clinical-stage portfolio in the past two decades reveals several trends, including a recent improvement in success rates in late-stage trials, an increase in overall portfolio size and higher success rates for biologics and partnered projects.
This article analyses the market for rheumatoid arthritis therapies, which is growing rapidly, with a range of new disease-modifying drugs poised to enter in the next few years.
The year 2015 saw the approval of six new targeted therapies for the treatment of non-small-cell lung cancer (NSCLC). This analysis discusses recently approved as well as late-stage compounds and examines how different drug classes will affect the NSCLC market.
This article presents a benchmarking analysis that identifies design parameters associated with improved performance in clinical R&D, and hence actions that companies can take to optimize their clinical development operations.
